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Abstract  
 
Risks for cardiovascular diseases (CVDs) other than myocardial infarction and stroke in the 
general COPD population are not well quantified. We used a matched cohort study design 
and Cox regression to estimate relative risks for 12 separate CVDs in a large population-
based cohort of COPD patients over a 12-year period.  Associations between COPD and 
individual CVDs were heterogeneous, with the highest relative risks observed for heart 
failure and diseases of the arterial circulation (in excess of 2.5 for those aged 64–75 years). 
Relative risks declined with increasing age but for most CVD outcomes remained unchanged 
over the study period.   
Words = 100 (100 permitted)  
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Introduction 
Investigation of cardiovascular disease (CVD) risks in people with chronic obstructive 
pulmonary disease (COPD) has focused on coronary heart disease, in particular myocardial 
infarction (MI), and stroke.1-3 Risks for other CVDs such as angina, atrial fibrillation, heart 
failure, and diseases of the arterial circulation are less well documented but evidence is 
accumulating that these too are elevated in COPD.4-7  By using UK electronic primary health 
care records (Clinical Practice Research Datalink (CPRD)), we have estimated relative risks 
for 12 separate CVD outcomes in a large population-based cohort of COPD patients over a 
12-year period.   
 
Methods 
A dynamic cohort of all patients with a GP-diagnosis of COPD prior to 31/12/2015 was 
drawn from CPRD using a validated algorithm.8 Exclusion criteria, as well as the criteria 
used to define the start and end of each person’s follow up are detailed in the online data 
supplement (see Appendix 1).   Individuals were assigned a smoking status (never, ex, 
current) based on information recorded in CPRD closest to their COPD diagnosis date.  
We defined 12 CVD outcomes – AAA (abdominal aortic aneurysm), angina, atrial 
fibrillation, heart failure, MI, peripheral artery disease (PAD), pulmonary artery 
hypertension (PAH), stroke (subdivided into all stroke excluding transient ischaemic attacks 
(TIAs), ischaemic stroke, haemorrhagic stroke, and TIAs) and sudden cardiac arrest (SCA) –  
and identified incident cases using Read codes.   
In the first part of our analysis, we estimated age- and gender-specific incidence rates for 
each of these 12 CVDs in people with a diagnosis of COPD. We then used a matched cohort 
study design and a Cox regression model to estimate relative risks for the same 12 CVDs, 
comparing people with and without COPD. In our primary analysis, we adjusted for sex 
and GP practice by matching and stratified our results by age group and calendar time 
(using three four-year consecutive time periods 2004–2007, 2008–2011, 2012–2015). In a 
secondary analysis we also adjusted for smoking. A more detailed description of the 
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methodology is provided in the online supplementary material (see Appendix 1). All 
statistical analyses were conducted using Stata version 14 (StataCorp, TX, USA). 
 
Results 
A total of 299,039 individuals with at least one specific COPD code in their primary 
healthcare record were identified, of whom 209,909 satisfied our inclusion criteria. The 
number of people identified equates to a UK COPD prevalence of 2–3%, in line with 
expectations.  
The characteristics of the base COPD cohort are summarised in Table 1. In this population, 
the risk of developing CVDs generally increased with age. However, there was little 
evidence to suggest that incidence rates have altered substantially over the last decade (see 
Appendix 2: Figure A2.1).  
Relative risks (expressed as hazard ratios) for all CVD subtypes decreased with increasing 
age; the inverse relationship between relative risk for CVD and increasing age was 
especially pronounced for atrial fibrillation, heart failure, coronary heart disease (angina, 
MI), and stroke outcomes (Figure 1). In the crude analysis (in which adjustment was made 
for matching variables only), we found no evidence of an association between COPD and 
any of our four stroke outcomes in the oldest age group.  For all other outcomes, the excess 
risk was evident at all ages. For most CVD outcomes, relative risks remained unchanged 
over the study period (see Appendix 2: Figure A2.2).  
 
Discussion  
We have shown that increased risks for CVD in people with COPD are not confined to MI 
and stroke, but exist across the spectrum of CVD subtypes. We further demonstrated that 
while relative risks for CVDs vary by age, these risks do not appear to have materially 
altered over the 12-year period of our study, implying that people with COPD are still at a 
disadvantage in terms of CVD risks compared with their COPD-free counterparts.  
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While in line with the findings of other studies, the inverse relationship between relative risk 
and age is a striking feature of our analysis (Figure 1),9 and suggests that in older age CVD 
risk is driven more by the mechanisms of ageing than by COPD per se. It is not clear why 
relative risk for CVD should be higher among younger COPD patients. It is possible that this 
high risk group represents a subset of susceptible individuals who as a consequence of a low 
maximally-attained lung function develop airflow limitation (and thus COPD) at a relatively 
early age. Factors that contribute to poor lung function in this group, such as low birth 
weight and environmental exposures, may well also be contributing to an increased risk for 
CVD in middle age.   
We found a considerable degree of heterogeneity in the magnitude of the relative risks 
across the individual CVD outcomes studied. While COPD was associated with an increased 
risk of all 12 outcomes, the highest hazard ratios were observed for AAA, PAD, PAH and 
heart failure. These patterns mirror those reported by Chen et al.1 who also ranked diseases 
of the pulmonary circulation and heart failure among the more “high-risk” outcomes in a 
meta-analysis of the prevalence of CVD comorbidities in COPD. Our heterogeneity patterns 
are also similar to those reported for the association between smoking and the initial (first) 
presentation of specific CVD outcomes by Pujades-Rodriguez et al.10  
Large sample size and a representative population-based COPD cohort identified using a 
validated algorithm with a high positive predictive value are the key strengths of our study 
design. Limitations include difficulties in characterising smoking status, differential 
misclassification of CVD outcomes and lack of adjustment for other potential confounders 
(see Supplementary material: Appendix 3). 
Taken together, our findings provide a strong case for a more aggressive management of 
CVD risks in COPD that is not confined to MI and stroke but extends to other conditions 
such as atrial fibrillation, heart failure and PAD. Our study also adds to the growing body of 
evidence that supports calls for a more integrated approach to the diagnosis and 
management of lung and heart disease which targets those in mid- to late-middle age. 
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Figures and tables (main paper) 
Figure captions 
Figure 1: Hazard ratios (HRs) for 12 cardiovascular disease outcomes, by age group, comparing 
people with and without COPD (HRs are derived from Cox proportional hazard models adjusted for 
sex and GP practice by matching only) 
See files: forest_plot01_hr_ageband_v4f.png; forest_plot02_hr_ageband_v4f.png; 
forest_plot03_hr_ageband_v4f.png 
 
Table 1:  Characteristics of the basea COPD cohort  
 
 All subjects  Men  Women 
 No. (% unless 
otherwise stated) 
 No. (% unless 
otherwise stated) 
 No. (% unless 
otherwise stated) 
      
All ages 209,909   109,406   100,503  
      
Age group      
  Under 55 years 44,553   (21.2)  22,338   (20.4)  22,215   (22.1) 
  55–64 years 55,467   (26.4)  29,766   (27.2)  25,701   (25.6) 
  65–74 years 58,721   (28.0)  31,606   (29.0)  27,115   (27.0) 
  75–85 years 42,081   (20.1)  21,575   (19.7)  20,506   (20.4) 
  Over 85 years 5,937      (4.3)  4,121     (3.8) 
 
 4,966     (4.9) 
Mean age at COPD  
  diagnosis (years; sd) 
65.84     (11.7)  65.72      (11.4)  65.98      (12.0) 
      
Smoking status      
  Never smoker 5,520       (2.6)  2,061      (1.9)  3,459       (3.4) 
  Ex-smoker 96,680     (46.1)  56,141    (51.3)  40,536     (40.3) 
  Current 89,505     (42.6)  44,678    (40.8)  44,827     (44.6) 
  Unknown  18,204     (8.7)  6,526      (6.0)  11,678     (11.6) 
 
a In order to compute relative risk for each of our 12 CVD outcomes, a series of 12 matched cohorts were created in which 
subjects who experienced the CVD in question prior to their diagnosis of COPD were excluded before being matched to a 
COPD-free control. The base cohort thus comprises all individuals with COPD meeting study inclusion criteria, save any 
subsequent exclusions for a prior CVD event.   
 
 
 
 
